Page last updated: 2024-12-04

buformin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Buformin: An oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

buformin : A member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2468
CHEMBL ID39736
CHEBI ID3209
SCHEMBL ID27451
SCHEMBL ID15762988
MeSH IDM0003015

Synonyms (88)

Synonym
buformina [inn-spanish]
glybigidum
biguanide, 1-butyl-
buformine
imidodicarbonimidic diamide, n-butyl-
einecs 211-726-4
n-butylbiguanide
buformin [usan:inn]
butylbiguanide
1-butyldiguanide
w 37
butformin
buformine [inn-french]
butylbiguanidum
glybigid
h 224
butyldiguanide
buforminum [inn-latin]
brn 0607037
butyl guanylguanidine
adebit
diabrin
butylbiguanide hydrochloride
biforon
sb 103
sindiatil
dbv hydrochloride
andere
panformin
buformine hcl
n-butyldicarbonimido/ic diamide/imido
biguanide, 1-butyl-, hydrochloride
nsc113665
1-butyl-3-carbamimidoyl-guanidine
1-butylbiguanide
C07674
692-13-7
buformin
DB04830
buformin (usan/inn)
D00595
DBV ,
NCGC00164533-01
CHEMBL39736
chebi:3209 ,
AKOS003382834
2-butyl-1-(diaminomethylidene)guanidine
NCGC00186641-01
NCGC00164533-02
dtxsid6046420 ,
tox21_112164
cas-692-13-7
dtxcid4026420
AKOS006228752
imidodicarbonimidicdiamide, n-butyl-
4-04-00-00582 (beilstein handbook reference)
unii-w2115e9c7b
buforminum
buformina
w2115e9c7b ,
buformin [mart.]
buformin [who-dd]
buformin [inn]
buformin [mi]
w-37
buformin [usan]
1-n-butylbiguanide
n-butylimidodicarbonimidic diamide
STL484281
SCHEMBL27451
tox21_112164_1
n,n-butylbiguanide
2-butyl-1-(diaminomethylene)guanidine
SCHEMBL15762988
n1-butylbiguanide
SR-01000944701-1
sr-01000944701
2-butyl-1-(diaminomethylidene)-guanidine
butylbiguanid
1215700-80-3
n-butylbiguanidine
HY-B2099
Q715104
buformin-d9 hydrochloride
CS-0017529
692-13-7 (free base)
EN300-6889932
n-butyl-1-carbamimidamidomethanimidamide

Research Excerpts

Overview

Buformin is a widely used as an antidiabetic agent but its renal excretion is still controversial. It is a more potent inhibitor of AGE formation than metformin.

ExcerptReferenceRelevance
"Buformin is an old anti-diabetic agent and manifests potent anti-tumor activities in several malignancies. "( Buformin suppresses proliferation and invasion via AMPK/S6 pathway in cervical cancer and synergizes with paclitaxel.
Chen, L; Li, J; Liu, Q; Tang, M; Wang, Y; Yu, J, 2018
)
3.37
"Buformin is a widely used as an antidiabetic agent but its renal excretion is still controversial. "( A new method for determination of buformin in plasma and urine by ion-paired reversed-phase HPLC with ultraviolet detection.
Iga, T; Kusama, M; Matsuno, K; Sugiyama, E; Yamada, Y; Yamamoto, T, 2002
)
2.04
"Buformin is a more potent inhibitor of AGE formation than metformin, and suggests that the amino group of buformin trap the carbonyl group of methylglyoxal to suppress formation of AGE."( Effect of buformin and metformin on formation of advanced glycation end products by methylglyoxal.
Hirano, K; Kato, M; Kiho, T; Usui, S, 2005
)
2.17

Treatment

ExcerptReferenceRelevance
"Buformin treatment resulted in significant increase of blood glucose values between 180 and 360 min after oral glucose challenge and in considerable improvement of hypoglycemia in nine obese patients with idiopathic reactive hypoglycemia and in the patient with chemical diabetes."( Treatment of reactive hypoglycemia with buformin.
Cabrijan, T; Sekso, M; Solter, M; Zjacić, V, 1975
)
1.24

Toxicity

ExcerptReferenceRelevance
"A survey of the literature leads to the conclusion that lactic acidosis should be considered as a side effect of therapy with biguanides."( [The importance of lactate acidosis as a side effect of biguanide therapy].
Förster, H, 1976
)
0.26

Bioavailability

ExcerptReferenceRelevance
" The rate of absorption decreased from the colon to the duodenum (colon greater than ileum greater than jejunum greater than duodenum)."( Intestinal oxalate absorption. I. Absorption in vitro.
Caspary, WF, 1977
)
0.26
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" We, therefore, consider a preventive administration of biguanides to be effective in long term or high dosage administration of glucocorticoides."( [Antagonistic action of prednisolone and buformin in the carbohydrate metabolism of healthy persons (author's transl)].
Bottermann, P; Ermler, R; Schweigart, U, 1976
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
hypoglycemic agentA drug which lowers the blood glucose level.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
radiosensitizing agentA drug that makes increases the sensitivity of tumour cells to radiation therapy.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antiviral agentA substance that destroys or inhibits replication of viruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
biguanidesA class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency30.05340.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency27.13900.000221.22318,912.5098AID1259247; AID743042; AID743054
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency6.91780.01237.983543.2770AID1645841
estrogen nuclear receptor alphaHomo sapiens (human)Potency15.22350.000229.305416,493.5996AID1259244; AID1259248; AID743080; AID743091
cytochrome P450 2D6Homo sapiens (human)Potency34.67130.00108.379861.1304AID1645840
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency13.33220.000627.21521,122.0200AID743202; AID743219
lamin isoform A-delta10Homo sapiens (human)Potency3.16230.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency13.33320.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency13.33320.001551.739315,848.9004AID1259244
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency3.82740.009610.525035.4813AID1479148
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Km48.80000.27005.695010.0000AID679316
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (71)

Assay IDTitleYearJournalArticle
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID188230Evaluated in alloxanized, diabetic rat for the percentage reduction in blood glucose level after 5 hr as compared to pretreatment blood glucose values at a dose of 300 mg of free base / kg body weight administered orally1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Chemistry and hypoglycemic activity of N-[[(Dialkylamino)alkoxy]phenyl]benzamidines.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1894461Synergistic antifungal activity against Candida glabrata assessed as fractional inhibitory concentration index in presence of voriconazole incubated for 18 hrs by checkerboard assay2021European journal of medicinal chemistry, Apr-15, Volume: 216Antimicrobial drugs bearing guanidine moieties: A review.
AID77196Evaluated in normal, fasted guinea pig for the percentage reduction in blood glucose level after 5 hr as compared to pretreatment blood glucose values at a dose of 30 mg of free base / kg body weight administered orally1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Chemistry and hypoglycemic activity of N-[[(Dialkylamino)alkoxy]phenyl]benzamidines.
AID1894462Synergistic antifungal activity against Candida glabrata assessed as fractional inhibitory concentration index in presence of amphotericin incubated for 18 hrs by checkerboard assay2021European journal of medicinal chemistry, Apr-15, Volume: 216Antimicrobial drugs bearing guanidine moieties: A review.
AID188905Percent reduction in blood glucose after perorally administration of compound at 29.2 mg/kg in in alloxanized rat1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Chemistry and hypoglycemic activity of benzimidoylpyrazoles.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID77204Percent reduction in blood glucose after perorally administration of compound at 30 mg/kg in in normal fasted guinea pig1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Chemistry and hypoglycemic activity of benzimidoylpyrazoles.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID188909Percent reduction in blood glucose after perorally administration of compound at 350 mg/kg in non-glucose-primed rat1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Chemistry and hypoglycemic activity of benzimidoylpyrazoles.
AID184645Lethal dose required to produce 50% lethality in male and female carworth farms CF-1 strain mice weighing 16-25 g administered intraperitoneally1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Chemistry and hypoglycemic activity of N-[[(Dialkylamino)alkoxy]phenyl]benzamidines.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID126666Evaluated in normal, fasted monkey for the percentage reduction in blood glucose level after 5 hr as compared to pretreatment blood glucose values at a dose of 70 mg of free base / kg body weight administered orally1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Chemistry and hypoglycemic activity of N-[[(Dialkylamino)alkoxy]phenyl]benzamidines.
AID188241Evaluated in glucose-primed, fasted rat for the percentage reduction in blood glucose level after 2 hr as compared to control groups at a dose of 100 mg of free base / kg body weight administered orally1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Chemistry and hypoglycemic activity of N-[[(Dialkylamino)alkoxy]phenyl]benzamidines.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID134584Lethal dose after peroral administration in mouse1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Chemistry and hypoglycemic activity of benzimidoylpyrazoles.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID188907Percent reduction in blood glucose after perorally administration of compound at 300 mg/kg in in adrenalectomized rat (p= 0.05)1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Chemistry and hypoglycemic activity of benzimidoylpyrazoles.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID188896Percent reduction in blood glucose after perorally administration of compound at 100 mg/kg in glucose-primed rat1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Chemistry and hypoglycemic activity of benzimidoylpyrazoles.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID188238Evaluated in glucose primed, adrenalectomized rat for the percentage reduction in blood glucose level after 2 hr as compared to pretreatment blood glucose values at a dose of 350 mg of free base / kg body weight administered orally1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Chemistry and hypoglycemic activity of N-[[(Dialkylamino)alkoxy]phenyl]benzamidines.
AID1894460Synergistic antifungal activity against Candida glabrata assessed as fractional inhibitory concentration index in presence of fluconazole incubated for 18 hrs by checkerboard assay2021European journal of medicinal chemistry, Apr-15, Volume: 216Antimicrobial drugs bearing guanidine moieties: A review.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID679316TP_TRANSPORTER: uptake in OCT1-expressing CHO cells2002The Journal of pharmacology and experimental therapeutics, Aug, Volume: 302, Issue:2
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID134583Lethal dose after intraperitoneal administration in mouse1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Chemistry and hypoglycemic activity of benzimidoylpyrazoles.
AID184646Lethal dose required to produce 50% lethality in male and female carworth farms CF-1 strain mice weighing 16-25 g administered orally1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Chemistry and hypoglycemic activity of N-[[(Dialkylamino)alkoxy]phenyl]benzamidines.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (164)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990112 (68.29)18.7374
1990's11 (6.71)18.2507
2000's17 (10.37)29.6817
2010's12 (7.32)24.3611
2020's12 (7.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.02 (24.57)
Research Supply Index5.21 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index49.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (4.60%)5.53%
Reviews6 (3.45%)6.00%
Case Studies16 (9.20%)4.05%
Observational0 (0.00%)0.25%
Other144 (82.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Incretin-based Drugs and the Risk of Heart Failure: A Multi-center Network Observational Study [NCT02456428]1,499,650 participants (Actual)Observational2014-03-31Completed
The Use of Incretin-based Drugs and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes [NCT02476760]1,417,914 participants (Actual)Observational2014-03-31Completed
Cinobufacini Tablets Combined With R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone)/CHOP in Treatment of Diffuse Large B Cell Lymphoma: A Phase II Randomized, Controlled and Multi-center Study [NCT02871869]Phase 2/Phase 3316 participants (Anticipated)Interventional2016-09-30Recruiting
The Use of Incretin-based Drugs and the Risk of Pancreatic Cancer in Patients With Type 2 Diabetes [NCT02475499]886,172 participants (Actual)Observational2014-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]